Načítá se...
Optimizing Polymyxin Combinations Against Resistant Gram-Negative Bacteria
Polymyxin combination therapy is increasingly used clinically. However, systematic investigations of such combinations are a relatively recent phenomenon. The emerging pharmacodynamic (PD) and pharmacokinetic (PK) data on CMS/colistin and polymyxin B suggest that caution is required with monotherapy...
Uloženo v:
| Vydáno v: | Infect Dis Ther |
|---|---|
| Hlavní autoři: | , , , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Springer Healthcare
2015
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4675771/ https://ncbi.nlm.nih.gov/pubmed/26645096 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40121-015-0093-7 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|